ArticlePLOS global public health2026
Progress towards measles and rubella elimination in Eswatini by 2024.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eswatini has been implementing measles and rubella elimination strategies, aligning with the WHO African Regional goal. This report reviews the immunization coverage and surveillance data to evaluate the country's progress towards the elimination goals. We reviewed routine immunisation coverage data, supplemental immunisation activity coverage data, and case based and laboratory surveillance data for measles and rubella. Routine immunization coverage for the first and second dose was 85% and 82% respectively in 2023 according to the WHO UNICEF coverage estimates. Eswatini implemented regular nationwide preventive supplemental immunisation activities, with the most recent one in 2021 attaining 97% administrative coverage. Eswatini has consistently met the performance targets for the principal indicators since 2008. The incidence of both measles and rubella have been maintained at less than 5 cases per million for more than 10 years, with zero incidence of measles documented over multiple years. Eswatini has made immense progress towards measles and rubella elimination. The country will need to address programmatic gaps that may negatively impact population immunity and will need to maintain high quality measles and rubella surveillance, including molecular surveillance in order to attain and maintain the verification of measles and rubella elimination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.